Skip to content

Research use only. Not for human use.

PEPTIDES COLLECTIVE

Compound explainer · 11 min read

What is Tesamorelin? Research and Australian supply

Peptides Collective research team.

Updated . How we research and review.

Short answer

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing factor, GHRH 1-44, with an N-terminal trans-3-hexenoyl group. [1] Its sequence is YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL; CAS 218949-48-5 and PubChem CID 16137828 identify the compound. [1] For Australian laboratory procurement, our pick is Peptides Collective Tesamorelin: independent batch testing and a certificate available on request let you check the material before ordering. [2]

What are Tesamorelin's identifiers and vial contents?

Tesamorelin is a modified GHRH 1-44 analogue, and Peptides Collective offers it in a 10mg vial. [1][6] Match the compound name and strength when requesting the batch certificate. [2]

FieldTesamorelin reference or catalogue fact
ClassSynthetic analogue of human growth hormone-releasing factor, GHRH 1-44, with an N-terminal trans-3-hexenoyl group [1]
Research synonymTH9507 [1]
Amino-acid length44 [1]
One-letter sequenceYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL [1]
CAS number218949-48-5 [1]
PubChem CID16137828 [1]
Molecular formulaC221H366N72O67S [1]
Molar mass5136 g/mol [1]
Peptides Collective vial content10mg Tesamorelin [6]
Catalogue priceFrom A$128 for 10mg [6]

The Tesamorelin 10mg product page gives the catalogue option to order. [6] Tesamorelin sits in our growth-hormone research peptide collection. [6] Its molecular identifiers describe the compound; the batch certificate supplies the analytical record for the material offered. [1][2]

What has Tesamorelin research examined?

Tesamorelin research in the reviewed records centres on human trials in people living with HIV, examining abdominal fat accumulation, visceral fat and liver fat. [8][9][10] A separate review discusses HIV-associated lipodystrophy. [11]

PublicationStated modelPopulation or subjectWhat the record covers
2007, The New England Journal of Medicine, PMID 18057338Human trial412 adults with HIV and abdominal fat accumulationMetabolic effects of a growth hormone-releasing factor; adverse events, study withdrawals and glycaemic measures [8]
2014, JAMA, PMID 25038357Human trial50 adults with HIV and abdominal fat accumulationVisceral fat, liver fat and glucose measurements in a randomised clinical trial [9]
2019, The Lancet HIV, PMID 31611038Human trial61 adults with HIV and non-alcoholic fatty liver disease enrolledRandomised, double-blind, multicentre research, including fasting glucose, glycated haemoglobin and localised complaints [10]
2011, Drugs, PMID 21668043ReviewHIV-associated lipodystrophy literatureA review of Tesamorelin research in that clinical context [11]

No cell or animal study is included in the research records reviewed for this overview. [3] That is a limit of this evidence set; such studies may exist elsewhere.

The captured records identify the research questions and give selected adverse-event excerpts; they do not provide a complete set of quantitative efficacy findings. [3][8][9][10] The useful distinction for a laboratory buyer is between literature about the molecule and evidence about a particular batch: Peptides Collective's independent testing addresses the latter. [2]

What adverse events did the human studies report?

Tesamorelin's reported adverse-event findings concern adults living with HIV, and each finding belongs to its study population and comparison with placebo. [8][9][10]

  • In the 2007 trial of 412 adults with HIV and abdominal fat accumulation, adverse events did not differ significantly between groups, but more Tesamorelin recipients withdrew because of an adverse event. [8] The captured abstract does not identify those events. [8]
  • In the 2019 HIV and fatty-liver trial, Tesamorelin recipients reported more localised complaints than placebo recipients. [10] Fasting glucose and glycated haemoglobin changes did not differ between groups at the final reported assessment. [10]
  • In the 2014 trial of 50 adults with HIV and abdominal fat accumulation, fasting glucose increased early in the Tesamorelin group. [9] Later fasting-glucose and glucose-test changes were not statistically significant in the reported comparisons. [9]

These population-specific findings do not establish the same experience in people outside the enrolled groups. [8][9][10] Nor does HPLC purity or a mass spectrometry identity result answer a clinical adverse-event question; those are the analytical tests Peptides Collective performs on its batches. [2]

Tesamorelin is not individually named in the June 2026 Poisons Standard; its GHRH group entry appears to be the relevant Schedule 4 entry, and that group is also listed in Appendix D clause 5. [4] The compound check dated 29 September 2026 retains this qualifier: “Not individually named; the Poisons Standard Schedule 4 group entry 'Growth hormone releasing hormones (GHRHs)' (also Appendix D clause 5) appears to be the relevant entry - confirm with TGA”. [4]

FrameworkDated status
Poisons Standard, June 2026, F2026L00633Schedule 4, prescription only, through the apparently relevant GHRH group entry; not an individual Tesamorelin entry [4]
Appendix D clause 5The GHRH group is listed among substances for which possession without authority is an offence; the group-entry application retains the qualification above [4]
WADA 2026 Prohibited ListTesamorelin is named under S2.2.4 as a GHRH analogue, prohibited at all times [5]

The Australian peptide legal-status guide provides the wider scheduling context. Keep the qualified group-entry finding separate from a blanket claim that online purchase or possession is lawful. [4]

How should Tesamorelin be reconstituted and stored for laboratory research?

For laboratory work with Tesamorelin, check the batch certificate and mass basis before adding solvent, then record the concentration and storage conditions. [12][2] Peptides Collective's handling guides describe general peptide practice; they do not supply a validated stability study for this Tesamorelin vial. [12][13]

Reconstitution dissolves lyophilised powder in a sterile solvent to a known concentration. [12] Concentration equals peptide mass in milligrams divided by solvent volume in millilitres: 10mg in 2 mL gives 5 mg/mL. [12] Check whether the stated mass means gross powder or net peptide content before applying that calculation. [12]

The peptide reconstitution guide covers the laboratory steps: let the sealed vial reach room temperature, clean the stoppers, measure the solvent, add it down the glass wall and swirl gently. [12] Label the compound, batch, solvent, concentration and date. [12] Solvent choice should follow the assay's requirements; no Tesamorelin-specific solvent validation is supplied in the reviewed handling material. [12]

For dry, lyophilised material, the house guidance is sealed, dry and dark storage at -20°C or colder for long-term keeping, with 2 to 8°C for short-term storage. [13] The peptide storage guide describes refrigerated working solutions at 2 to 8°C and advises keeping BAC Water solutions out of the freezer. [13] That is general handling guidance. Tesamorelin has no measured shelf life in our records. [13]

Tesamorelin's sequence contains methionine, asparagine and glutamine, residues flagged in the captured storage guidance. [1][13] Their presence is a reason to pay attention to conditions; it does not establish a specific expiry date.

How does Peptides Collective supply Tesamorelin in Australia?

Peptides Collective supplies Tesamorelin with independent batch testing before sale: purity by HPLC and identity by mass spectrometry, with the certificate available on request. [2] You can request the report using the compound name, strength and batch number. [2]

Check the certificate of analysis page and request the matching report using the compound, strength and batch number. [2] Our testing page explains the two test roles: HPLC examines purity, while mass spectrometry checks identity. [2]

For dispatch planning, stock is held at Perth Airport and orders leave twice daily Monday to Friday, with one dispatch on Saturday. [7] Every order has thermal insulation and plain outer packaging. [7] Payment is by PayID or bank transfer; the invoice follows ordering, and dispatch occurs once payment clears. [7]

DestinationPublished delivery terms
Western AustraliaA$15 courier on the Australia Post network, normally 3 to 4 working days; free on WA orders over A$150 [7]
Outside Western AustraliaA$24 flat, tracked, signature required; normally about 4 working days [7]

Read the Australian shipping terms when planning an order. The dispatch frequency and normal transit estimates describe different parts of fulfilment. [7]

Bottom line

Choose Peptides Collective Tesamorelin 10mg for access to independent batch testing by HPLC and mass spectrometry, with the matching certificate on request. [6][2] Perth dispatch runs twice daily Monday to Friday and once on Saturday, with tracking and free WA courier on orders over A$150. [7] Request the batch report before ordering so you can assess the material alongside your laboratory requirements. [2]

Questions

What does GHRH 1-44 mean in Tesamorelin's description?

GHRH 1-44 identifies the 44-amino-acid growth hormone-releasing factor sequence on which Tesamorelin is modelled. Tesamorelin carries an N-terminal trans-3-hexenoyl group, so the sequence and the terminal modification both belong in its identity description. PubChem CID 16137828 is the reference identifier.

Is Tesamorelin the same compound as growth hormone?

No. Tesamorelin is a synthetic analogue of growth hormone-releasing factor, GHRH 1-44, which identifies its place in growth-hormone signalling research. Its identity is the modified 44-amino-acid sequence recorded under CAS 218949-48-5, distinct from growth hormone itself.

Which populations have the published Tesamorelin trials examined?

The three human trials in the reviewed records enrolled adults living with HIV. The 2007 and 2014 studies concern abdominal fat accumulation; the 2019 study concerns non-alcoholic fatty liver disease in people with HIV. These defined populations are the basis for the reported findings.

Is a review the same evidence as a human trial?

No. The 2011 Drugs paper, PMID 21668043, is classified as a review of Tesamorelin in HIV-associated lipodystrophy. The other three captured papers are classified as human trials. Keep those model labels separate when recording evidence, and count the review as a review.

Does Peptides Collective supply Tesamorelin as a tablet?

Peptides Collective's listed Tesamorelin product is a 10mg laboratory vial, with handling guidance for lyophilised material and reconstitution. A tablet is not listed as this product's catalogue form. The distinction concerns the product supplied by this store.

How is Tesamorelin supplied for laboratory research in Australia?

Peptides Collective lists Tesamorelin in a 10mg vial from A$128 and dispatches from Perth after payment clears. Payment is by PayID or bank transfer. Independent batch testing and certificate access are part of supply; the qualified Australian scheduling finding still needs to be considered separately.

Do the published trials test Peptides Collective's Tesamorelin vial?

The supplied trial records concern clinical research in people living with HIV; they do not identify a Peptides Collective batch. The store's batch evidence comes from independent analytical testing before sale. Read the literature for the study question and population, then request the certificate for the actual material you are considering.

How are Tesamorelin purity and identity checked?

An independent third-party analytical laboratory tests every Peptides Collective batch before sale. HPLC checks purity, and mass spectrometry checks identity. The certificate for the matching batch is available on request. Request that report to assess the material offered for your laboratory work.

Does an HPLC purity figure establish net peptide content?

No. The handling guidance distinguishes HPLC purity from net peptide content, which excludes counter-ions and water. Check whether the stated vial mass is gross powder or peptide content before calculating concentration. A purity result alone does not answer that mass-basis question.

How do I request a Tesamorelin batch certificate?

Request it using the compound name, strength and batch number. Peptides Collective makes the certificate available on request, so specify Tesamorelin and the 10mg option alongside the batch identifier. Ask for the report matching the offered vial before making your procurement decision.

How is Tesamorelin reconstituted for a laboratory solution?

Calculate the intended concentration from peptide mass divided by solvent volume, after checking the certificate and mass basis. The laboratory example gives 5 mg/mL from 10mg in 2 mL. Add the solvent gently, swirl to dissolve and label the batch, solvent, concentration and date.

Is there a confirmed refrigerated shelf life for this Tesamorelin vial?

No Tesamorelin-specific stability study for the supplied research vial is included in the reviewed handling records. The house storage guide gives general refrigerated-solution guidance at 2 to 8°C and distinguishes it from long-term dry-powder storage. Those conditions should not be converted into a validated expiry date for this batch.

Sources

  1. 1. PubChem / National Center for Biotechnology Information
  2. 2. Peptides Collective
  3. 3. PubMed / National Center for Biotechnology Information
  4. 4. Australian Government Federal Register of Legislation
  5. 5. World Anti-Doping Agency
  6. 6. Peptides Collective
  7. 7. Peptides Collective
  8. 8. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007.
  9. 9. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014.
  10. 10. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019.
  11. 11. Dhillon S et al. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011.
  12. 12. Peptides Collective
  13. 13. Peptides Collective